Novartis Ag

Ciba-geigy Corporation

Novartis Corporation

Peter Traxler

Guido Bold

J&ouml;rg Frei

Jakob Nuesch

Pascal Furet

Marc Lang

Giorgio Caravatti

Hans-Georg Capraro

Jorg Frei

Karl-Heinz Altmann

Thomas Schupp

Jeanette Marjorie Wood

David Raymond Stover

Helmut Mett

Wolfgang K-d Brill

Uwe Trinks

Carl-Henrik Heldin

Wilhelm Kump

Oskar Wacker

Terence O'Reilly

Markus Wartmann

John David Rothermel

Peter J Houghton

Klaus Muller

Ralf Brandt

Elisabeth Buchdunger

Johannes Gruner

Kristian Pietras

Arne Östman

Wolfgang Karl-Diether Brill

The present invention relates to the use of imatinib of the following formula or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a cancer that expresses breast cancer resistant protein (BCRP) in a human subject in need of such a treatment.

Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents

The present invention relates to a combination comprising N-{5-[4-(4-methyl-piperazino-methyl) -benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and an epothiione derivative; pharmaceutical composition comprising said combination; method of treatment comprising said combination; and commercial packages comprising said combination.

Combination comprising a signal transduction inhibitor and an epothilone derivative

The invention relates to 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula I wherein the symbols and substituents are as defined in the description, to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives&#x2014;alone or in combination with one or more other pharmaceutically active compounds&#x2014;for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumour.

4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives

The invention relates to 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula I wherein the symbols and substituents are as defined in the description, to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives&#x2014;alone or in combination with one or more other pharmaceutically active compounds&#x2014;for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumor.

7H-pyrrolo[2,3-d]pyrimidine derivatives

The invention relates to 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula I wherein the symbols and substituents are as defined in the description, to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives-alone or in combination with one or more other pharmaceutically active compounds-for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumour 

Phthalazines with angiogenesis inhibiting activity

Pyrido-, pyrimido-, pyridazo- and pyrazo- pyridazines having angiogenesis inhibiting activity

The invention relates to compounds of formula I,

4-Amino-1H-pyrazolo&lsqb;3,4-d&rsqb;pyrimidine derivatives of formula I

Pyrimidine derivatives and processes for the preparation thereof

There are described 7H-pyrrolo&lsqb;2,3-d&rsqb;pyrimidine derivatives of the formula I

Substituted pyrrolopyrimidines and processes for their preparation

Pyrrolopyrimidines and processes for the preparation thereof

Pyrrolopyrimidines and processes for their preparation

The invention relates to the use of the compounds mentioned below in the therapeutic treatment of tumor diseases and other proliferative diseases, such as psoriasis, and to novel compounds of that type. The compounds are compounds of formula I ##STR1## wherein n is from 0 to 5 and, when n is not 0,

Pyrrolopyrimidine derivatives having pharmacological activity

Pyrazole derivatives and processes for the preparation thereof

The invention relates to the use of the compounds mentioned below in the therapeutic treatment of tumour diseases and other proliferative diseases, such as psoriasis, and to novel compounds of that type. The compounds are compounds of formula I ##STR1## wherein n is from 0 to 5 and, when n is not 0,

Growing community of inventors

Schoenenbuch, Switzerland

Peter Traxler